Bayer, Chiesi address respiratory medical needs in China
Print Edition
Bayer and Chiesi Farmaceutici S.p.A (Chiesi Group), announced on Monday that they have entered into a co-promotion agreement for Clenil and Foster in China, two products of Chiesi Group’s established portfolio in the respiratory therapeutic area.
The partnership aims to integrate commercial expertise and resources of both companies in China to improve access to treatment options for Chinese patients suffering from respiratory diseases.
Chronic respiratory diseases are among the major noncommunicable diseases in China. Two of the most common are asthma and chronic obstructive pulmonary disease (COPD), both of which lead to high unmet medical needs among the Chinese population.
A national study shows that the country is estimated to have more than 45.7 million adults with asthma, only around 5.6 percent of whom have received proper treatment. In addition, around 100 million Chinese people are suffering from COPD, accounting for 8.6 percent of the country’s adult population.
“As a global leader with over 85 years of track record and expertise in treating respiratory diseases, Chiesi is fully committed to the care and improvement of patients’ quality of life,” said Davide Dalle Fusine, general manager of Chiesi Pharmaceutical (Shanghai) Co Ltd. “Through this new partnership with Bayer, we would further expand access to benefit more patients in China. We are excited to join forces with Bayer and to contribute more in the management of chronic respiratory diseases.”
Chronic respiratory diseases, together with cardiovascular diseases and diabetes, are prioritized by the Chinese central government in its Healthy China Action Plan in efforts to address major health challenges caused by the prevalence of chronic diseases.
“In support of the Healthy China strategy, Bayer is dedicated to fulfilling its commitment to advancing chronic disease management and providing comprehensive solutions by leveraging our expertise in health care complemented by external know-how through partnerships,” said Wei Jiang, executive vice president and president of Bayer Pharmaceuticals Region China & APAC and president of Bayer Group China.
“We are pleased that the partnership with Chiesi expands our efforts to a broader spectrum of respiratory diseases, which enables us to help more patients suffering from respiratory disease to benefit from Chiesi’s established treatments. Collaborating with outstanding partners like Chiesi is a cornerstone of Bayer’s strategy to transform innovation into meaningful solutions for patients in China.”
In China, Clenil (beclometasone) is approved by the National Medical Products Administration for treating asthma and symptom relief of bronchus obstruction in adults and children. Foster (beclomethasone/formoterol) is approved in China for the regular treatment of asthma in adult patients. Foster utilizes Chiesi’s proprietary Modulite technology, which creates an extra fine solution enabling more even distribution in the lung starting from a lower dose of corticosteroid.
Bayer continues to intensify its partnering efforts in China on delivering values for local patients with chronic diseases. This May, Bayer announced a commercial agreement with WaveForm Technologies Inc. to provide innovative glucose monitoring solutions to patients and physicians in China. In addition, Bayer has been actively collaborating with industry associations, health care professionals and other partners to advance diabetes management through integrated approaches including public education, screening, prevention and treatment.
For example, since 2019, Bayer has been working with the China Health Promotion Foundation on the Diabetes Prevention project.
This initiative leverages both an online interactive platform and on-site programs such as expert consultation and community education activities to raise public awareness and health literacy on diabetes prevention and treatment, thus helping to improve outcome of diabetes management.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 沪ICP证：沪ICP备05050403号-1
- |
- 互联网新闻信息服务许可证：31120180004
- |
- 网络视听许可证：0909346
- |
- 广播电视节目制作许可证：沪字第354号
- |
- 增值电信业务经营许可证：沪B2-20120012
Copyright © 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
